Table 1 Descriptive characteristics of data.

From: Repurposing antibiotic resistance surveillance data to support treatment of recurrent infections in a remote setting

 

E. coli UTI

S. aureus SSTI

Number of patients

30,932

43,909

Number of males [%]:females [%]*

2,913 [10]:25,689 [90]

20,700 [55]:16,983 [45]

Age (years), median [IQR]*

43 [25–66]

34 [15–53]

Number of infection episodes [%]

84,585

88,999

Number of infection episodes per patient, median [IQR]

2 [2, 3]

2 [1–3]

Duration (days) of infection episodes, median [IQR]§

16 [7–25]

6 [2–18]

Duration (days) between infection episodes, median [IQR]

273 [99–716]

319 [109–828]

Number of isolates [%]

98,651

121,755

Number of isolates per patient, median [IQR]

2 [2, 3]

2 [2, 3]

Number of isolates per infection episode, median [IQR]

1 [1–1]

1 [1–1]

Duration (days) between isolates, median [IQR]

162 [41–552]

145 [25–584]

Antibiotics included in analysis [percentage of isolates tested]‡

amp [97]; amc [99]; cfz [99]; ctx [98]; cip [50]; nit [7]; trm [7]; sxt [7]

cln [85]; ery [99]; mth [87]; pen [84]; sxt [96]

  1. *At first isolate collected per unique patient; sex unknown for 2,330 (8%) and 6,226 (14%) patients with a UTI and SSTI respectively (age/sex not available from Territory Pathology).
  2. §Excluding infection episodes with only one isolate.
  3. ‡amp: ampicillin; amc: amoxicillin-clavulanate; cfz: cefazolin; ctx: ceftriaxone; cip: ciprofloxacin; cln: clindamycin; ery: erythromycin; mth: methicillin (flucloxacillin in Western Diagnostic Pathology data (up until end of 2014 only), flucloxacillin in Pathology Queensland data, oxacillin in Territory Pathology data); nit: nitrofurantoin; pen: penicillin; trm: trimethoprim; sxt: trimethoprim-sulfamethoxazole.
  4. Note: all statistics calculated after excluding patients with only one isolate; 3,990 patients had both ≥ 1 UTI and ≥ 1 SSTI.
Back to article page